|
Post by phdedieu12 on Oct 10, 2023 15:20:33 GMT -5
Could the analyst upgrade be related to the conferences mnkd recently attended and many people naysayed? YES!
|
|
|
Post by cjm18 on Oct 10, 2023 20:03:04 GMT -5
I can only see the 1 year timeframe rating. What is his overall rating? Looks like he had a big winner last year, over 195% gain. Andreas Argyrides Wedbush Wall Street Analyst #8,055 out of 8,566 Wall Street Analysts #30,072 out of 35,397 experts 43 out of 144 ratings made a profit Out of a possible 5 stars, Argyrides rating is a bit under one half a star. But as we used to say in baseball when a hitter was mired in an awful slump, "he's due!!" Xbi is down 37% since he started with the company in July 2020. His average return is -9%.
|
|
|
Post by olebob1 on Oct 10, 2023 20:42:48 GMT -5
Andreas Argyrides Wedbush Wall Street Analyst #8,055 out of 8,566 Wall Street Analysts #30,072 out of 35,397 experts 43 out of 144 ratings made a profit Out of a possible 5 stars, Argyrides rating is a bit under one half a star. But as we used to say in baseball when a hitter was mired in an awful slump, "he's due!!" Xbi is down 37% since he started with the company in July 2020. His average return is -9%. Ouch!
|
|
|
Post by olebob1 on Oct 10, 2023 20:50:29 GMT -5
I can only see the 1 year timeframe rating. What is his overall rating? Looks like he had a big winner last year, over 195% gain. Andreas Argyrides Wedbush Wall Street Analyst #8,055 out of 8,566 Wall Street Analysts #30,072 out of 35,397 experts 43 out of 144 ratings made a profit Out of a possible 5 stars, Argyrides rating is a bit under one half a star. But as we used to say in baseball when a hitter was mired in an awful slump, "he's due!!" Why used to say in baseball? Is that not true today? MNKD is due, biggly!!!
|
|
|
Post by cretin11 on Oct 10, 2023 20:58:00 GMT -5
I don’t watch much baseball these days, glad they still say that! A great expression that works well in everyday life too 😄
|
|
|
Post by JEvans on Oct 10, 2023 22:07:54 GMT -5
I don’t watch much baseball these days, glad they still say that! A great expression that works well in everyday life too 😄 Cretin, we are due! Over due! See even the analyst believes we're going to $10 But we don't need analyst to tell us that !
|
|
|
Post by akemp3000 on Oct 11, 2023 6:27:02 GMT -5
Keep in mind analysts often track many companies while seeking attention, clicks and new followers. Their investigations are too often limited to simplistic overviews. A much more knowledgeable and deeper analysis comes from here at Proboards where even the tiniest of weeds are investigated and analyzed
|
|
|
Post by letitride on Oct 18, 2023 1:17:59 GMT -5
Good analysis of Mannkind in an SA article by Stephen Ayers. I picked it up over on Stock Twits
|
|
|
Post by akemp3000 on Oct 18, 2023 4:58:30 GMT -5
Agree it was a positive article though peppered numerous times with the typical cya "cautious optimism". I don't believe there was anything in the article we didn't already know. I'm not even sure he mentioned the forthcoming pediatric approval that's expected, nor the anticipated turn to profitability in the near future. Maybe he did since I just scanned the article hoping to find something new. IMO, it was an example of another simplistic overview by an analyst. Still much better than a LFD article from SA. Speaking of LFD, it would be good to see a new bashing article from him as it usually precedes a nice move up in the share price.
|
|
|
Post by sportsrancho on Oct 18, 2023 18:49:49 GMT -5
But isn’t this a new author? The point is he likes us he’ll write favorable articles down the line, we needed that!
|
|
|
Post by wyattdog on Nov 14, 2023 12:00:43 GMT -5
Oppenheimer Adjusts MannKind Price Target to $5.50 From $6.50, Maintains Outperform Rating 8:21 AM ET, 11/14/2023 - MT Newswires 08:21 AM EST, 11/14/2023 (MT Newswires) -- MannKind (MNKD) has an average rating of Buy and price targets ranging from $5 to $10, according to analysts polled by Capital IQ. (MT Newswires covers equity, commodity and economic research from major banks and research firms in North America, Asia and Europe. Research providers may contact us here: www.mtnewswires.com/contact-us)Price: 3.51, Change: -0.03, Percent Change: -0.85
|
|
|
Post by sla55 on Jan 4, 2024 11:36:51 GMT -5
MannKind (NASDAQ:MNKD) Rating Reiterated by HC Wainwright Written by MarketBeat January 4, 2024 MannKind's stock had its "buy" rating reaffirmed by stock analysts at HC Wainwright in a note issued to investors on Thursday, Benzinga reports. They presently have a $7.50 price objective on the biopharmaceutical company's stock. HC Wainwright's price target indicates a potential upside of 102.70% from the stock's current price. A number of other research firms have also commented on MNKD. StockNews.com began coverage on MannKind in a research note on Thursday, October 5th. They set a "hold" rating on the stock. Wedbush began coverage on MannKind in a research note on Monday, October 9th. They set an "outperform" rating on the stock. MannKind Stock Performance MannKind stock opened at $3.70 on Thursday. The firm has a market capitalization of $997.45 million, a price-to-earnings ratio of -30.83 and a beta of 1.31. MannKind has a fifty-two week low of $3.30 and a fifty-two week high of $5.75. The stock's fifty day moving average is $3.72 and its two-hundred day moving average is $4.13. www.marketbeat.com/instant-alerts/nasdaq-mnkd-reiterated-rating-2024-01-04/
|
|
|
Post by sandstorm on Jan 5, 2024 6:44:15 GMT -5
HC Wainwright & Co. Reiterates Buy on MannKind, Maintains $7.5 Price Target Benzinga Newsdesk (Benzinga Newswire) HC Wainwright & Co. analyst Oren Livnat reiterates MannKind (NASDAQ:MNKD) with a Buy and maintains $7.5 price target. Copyright notice: © 2022 Benzinga.com. Benzinga does not provide investment advice. All rights reserved. Provided by SyndiGate Media Inc. (Syndigate.info).
|
|
|
Post by neil36 on Jan 8, 2024 5:30:16 GMT -5
INVESTARS ANALYST ACTIONS - PUBLIC
2:20 PM ET 01/07/2024
On January 7, 2024 Trading Central resumed coverage for MANNKIND ORD SHS with a BUY recommendation.
|
|
|
Post by cppoly on Jan 8, 2024 7:12:00 GMT -5
With the recent coverage and buy ratings, what's going to be the tipping point?
Seems like no one is paying attention to these coverages. Is it because we need a lot more analysts or is it because we're not getting coverage from the right ones?
|
|